Evidence map›Paper›PMID 36910368›Full record

ArticleAfrican health sciences2022

Aspergillus-specific IgM/IgG antibody serostatus of patients hospitalized with moderate-critical COVID-19 in Uganda.

Felix Bongomin, Richard Kwizera, Emmanuel Mande, Sharley Melissa Aloyo, Beatrice Achan, Martha Namusobya, Senai Goitom Sereke, Charles Batte, Sarah Kiguli, Joseph Baruch Baluku and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in African health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Felix BongominDepartment of Medical Microbiology and Immunology, Gulu University Medical School, Gulu Uganda.
Richard KwizeraTranslational research laboratory, Department of Research, Infectious Diseases Institute, College of Health Sciences, Makerere University, P.O Box 22418, Kampala, Uganda.
Emmanuel MandeTranslational research laboratory, Department of Research, Infectious Diseases Institute, College of Health Sciences, Makerere University, P.O Box 22418, Kampala, Uganda.
Sharley Melissa AloyoDepartment of Immunology and Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda.
Beatrice AchanDepartment of Medical Microbiology, College of Health Sciences, Makerere University, Kampala, Uganda.
Martha NamusobyaDepartment of Internal Medicine, Mulago National Referral Hospital, Kampala, Uganda.
Senai Goitom SerekeDepartment of Radiology and Radiotherapy, College of Health Sciences, Makerere University, Kampala, Uganda.
Charles BatteMakerere University Lung Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Sarah KiguliDepartment of Pediatrics and Child Health, College of Health Sciences, Makerere University, Kampala, Uganda.
Joseph Baruch BalukuDepartment of Internal Medicine, Mulago National Referral Hospital, Kampala, Uganda.
Moses L JolobaDepartment of Immunology and Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda.
Bruce J KirengaMakerere University Lung Institute, College of Health Sciences, Makerere University, Kampala, Uganda.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invasive pulmonary aspergillosis is known to complicate the coronavirus diseases-2019 (COVID-19), especially those with critical illness. We investigated the baseline anti-Aspergillus antibody serostatus of patients with moderate-critical COVID-19 hospitalized at 3 COVID-19 Treatment Units in Uganda. All 46 tested patients, mean age 30, and 11% with underlying respiratory disease had a negative serum anti-Aspergillus IgM/IgG antibody immunochromatographic test on day 3 (mean) of symptom onset (range 1-26), but follow up specimens to assess seroconversion were not available.

Indexed as

COVID-19AdultAntibodies, ViralCOVID-19 Drug TreatmentHumansImmunoglobulin GImmunoglobulin MSensitivity and SpecificityUgandaAntibodies, ViralImmunoglobulin GImmunoglobulin MCOVID-19critical illnessInvasive pulmonary aspergillosisUganda

Identifiers

PMID36910368
PMCPMC9993298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.